Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $21.11 Million |
|---|---|
| Enterprise Value | $-880,094.00 |
| Earnings per Share | $- |
| Beta | 2.09 |
| Outstanding Shares | 0 |
| P/E Ratio | -1.75 |
|---|---|
| PEG | -0.69 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -4.2 |
| Debt to Equity | 0.16 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It dev...